$5.720
-0.127 (-2.22%)收盘时
ZURA 资讯
ZURA 事件
Sandeep Kulkarni: Strong Execution on tibulizumab Programs, Funding Expected Through 2028
"The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now complete in both TibuSHIELD and TibuSURE-each exceeding its initial enrollment target-underscoring growing conviction in dual IL-17 and BAFF inhibition," said Sandeep Kulkarni, CEO. "We are excited to nominate polymyalgia rheumatica as the third indication for tibulizumab, a debilitating disorder with high unmet need and important evidence supporting the roles of both IL-17 and BAFF. With cash expected to fund planned operations through at least the end of 2028, we believe we are well positioned-operationally, financially, and scientifically-as we approach our first topline readout in the fourth quarter of this year."
Tenaya Therapeutics Appoints Eric Hyllengren as CFO
Tenaya Therapeutics (TNYA) announced the appointment of Eric Hyllengren as CFO, effective July 13. In this role, he will oversee financial strategy, capital allocation, investor relations and corporate development. He most recently served as CFO and executive VP of Zura Bio (ZURA).
Zura Bio Announces Updates on Tibulizumab Programs
Zura Bio announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target enrollment, with 247 participants enrolled. Zura remains on track to complete enrollment of the Phase 2 TibuSURE trial of tibulizumab in adults with early diffuse cutaneous SSc in early July. The TibuSURE trial has already exceeded the target enrollment of 80 participants. Exceeding enrollment targets in both TibuSHIELD and TibuSURE reflects the significant unmet need facing patients with HS and SSc. Topline data from TibuSHIELD are expected in the fourth quarter of 2026. Topline data from TibuSURE are expected in H1 2027. Building on tibulizumab's bispecific mechanism targeting both interleukin-17 and B cell activating factor, Zura plans to initiate a Phase 2 study in a third immune-mediated indication by year end 2026. Indication expansion of tibulizumab reflects Zura's belief in the broad potential of IL-17 and BAFF dual pathway inhibition across immune-mediated diseases. Zura plans to announce the new indication prior to study initiation.
Zura Cash and Cash Equivalents at $225.6M
Cash and cash equivalents were $225.6M as of March 31, 2026. Consistent with prior guidance and inclusive of the planned third-indication study, Zura continues to expect its existing cash to fund planned operations through at least the end of 2028.
Zura Bio Grants New CBO 600,000 Share Option Award
Zura Bio granted an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares to Muzammil Mustufa, the Company's new CBO. The award was approved by the Compensation Committee of the Company's Board of Directors and granted outside the Company's 2023 Equity Incentive Plan with a grant date of May 13, 2026, as an inducement material to Mr. Mustufa's employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The award is subject to the terms and conditions and other provisions set forth in the Company's Plan and the award agreement thereunder. The Option has an exercise price of $4.80 per Class A Ordinary Share, which is equal to the closing price of Zura's Class A Ordinary Shares on May 13, 2026. The Option will vest over four years, with one fourth of the shares subject to the Option vesting on the one year anniversary of the vesting commencement date, and the remaining shares subject to the Option vesting in equal quarterly installments thereafter, subject to Mr. Mustufa's continuous service through each such vesting date.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。